Extension of nasal anti-Staphylococcus aureus efficacy of lysostaphin by its incorporation into a chitosan-o/w cream.
Nasal colonization of Staphylococcus aureus (S.aureus) is known as a significant risk factor for nosocomial infections, and clearance of its nasal colonization greatly reduces the risk. In the present study the preparation and characterizations of the chitosan-o/w cream incorporated with lysostaphin (CCL) were described. It showed that the concentration of incorporated lysostaphin had a direct relationship with its release behavior from the cream. It was rapid at 2 and 3.5 mg lysostaphin/g cream and of a more sustained pattern at 5 mg lysostaphin/g cream. Efficacy of lysostaphin released from the CCL cream to inhibit S.aureus growth was higher than that of lysostaphin delivery routinely treated, as demonstrated by the reduction of the mucociliary transport rate (MTR) in contrast to the control graphite particles (p < 0.05). Therefore, it is concluded that drug delivery by the CCL holds its potential as a local nasal anti-S.aureus infection.
Cui
Fuying
F
State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, PR China.
Li
Guodong
G
Huang
Jinjiang
J
Zhang
Jien
J
Lu
Min
M
Lu
Wanying
W
Huang
Qingshan
Q
D000281:Administration, Intranasal; D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical; D048271:Chitosan / Q000008:administration & dosage / Q000493:pharmacokinetics; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D016503:Drug Delivery Systems; D004655:Emulsions; D006801:Humans; D008248:Lysostaphin / Q000008:administration & dosage / Q000493:pharmacokinetics; D008422:Materials Testing; D051379:Mice; D008819:Mice, Nude; D008826:Microbial Sensitivity Tests; D009079:Mucociliary Clearance / Q000187:drug effects; D009297:Nasal Mucosa / Q000187:drug effects; D009823:Ointment Bases; D010577:Petrolatum / Q000494:pharmacology; D051381:Rats; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity
D000891:Anti-Infective Agents, Local; D004655:Emulsions; D009823:Ointment Bases; D010577:Petrolatum; D048271:Chitosan; D008248:Lysostaphin